Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells

Takeshi Nagashima1, Masaaki Oyama, Hiroko Kozuka-Hata

  • 1Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, Yokohama, Kanagawa 230-0045, Japan.

Cancer Genomics & Proteomics
|September 30, 2008
PubMed

Insights

This study identified proteins and genes activated by epidermal growth factor (EGF) and heregulin (HRG) in breast cancer cells. HRG activated cancer-related pathways, while EGF did not show overlapping gene expression.

Area of Science:

  • Molecular Biology
  • Cellular Biology
  • Cancer Research

Background:

  • Cellular signal transduction and gene expression are critical for adapting to physiological changes.
  • Understanding immediate molecular responses to growth factor stimulation is key in cancer research.

Purpose of the Study:

  • To identify proteins and genes activated by ErbB receptor ligands, epidermal growth factor (EGF) and heregulin (HRG) in MCF-7 breast cancer cells.
  • To compare the proteomic and transcriptomic responses to EGF and HRG stimulation.

Main Methods:

  • Utilized stable isotopic labeling using amino acids in cell culture (SILAC) for proteomic analysis.
  • Employed Affymetrix gene expression arrays for transcriptome analysis.
  • Analyzed overlapping data between proteomic and transcriptomic datasets.

Main Results:

  • Low overlap between proteomic and transcriptomic data for HRG (5 common hits) and none for EGF.
  • HRG-stimulated genes included ERBB2, NEDD9, MAPK3, JUP, and EPHA2.
  • HRG-induced pathways significantly associated with bladder cancer, chronic myeloid leukemia, and pancreatic cancer.

Conclusions:

  • EGF and HRG elicit distinct proteomic and transcriptomic responses in breast cancer cells.
  • HRG stimulation activates cancer-related signaling pathways.
  • Proteomic data for both ligands showed enrichment in Axon guidance, ErbB signaling, and VEGF signaling pathways.